Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCB Insights

CEO Interview: Orq.ai

View original at cbinsights.com
CB Insights - Enterprise Ai Title: CEO Interview: Orq.ai Date: 2026-04-08 17:14 Source: https://www.cbinsights.com/research/ceo-interview-orq-ai/ <h4><span style="font-weight: 400;"><strong>Cameron McKelvie, Head of AI Implementation at <a href="https://app.cbinsights.com/profiles/c/AYrgn?tab=overview">Orq.ai</a></stro…
Opening lines of the source · CB Insights · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI doesn't work well when it is siloed within a technical team and removing the developer will be required for businesses to scale their usage on a large transformational level

    60% confidence
  • Higher level of AI understanding in the market would enable 10x growth by allowing sales conversations to start at step 4 or 5 instead of level 0

    60% confidence
  • With AWS Bedrock and Azure Foundry, costs tend to go up exponentially, not linearly with usage, and additional functionalities require extra payment

    60% confidence
  • The number of agents being used is going to 10x over the next 10 months in an enterprise setting

    60% confidence
  • A lot of institutions, particularly financial, defence, and governance institutions, are making an active effort to look at their supply chain and buy more European due to EU sovereignty concerns and US government instabilities

    60% confidence
  • Companies often use 5 different tools to do what one tool should be able to do in AI management

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com